NCT05858255 Hjernegym - Effects of Exergaming in Psychosis: a Clinical Intervention Study
| NCT ID | NCT05858255 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sykehuset i Vestfold HF |
| Condition | Schizophrenia; Psychosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2023-03-29 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 48 participants in total. It began in 2023-03-29 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical intervention study is to investigate the effects of exergaming on cognition and other clinical symptoms in outpatient individuals with schizophrenia. The main questions it aims to answer are: Will an exergaming intervention contribute to improved cognition and reduced clinical symptoms, as well as enhanced physical health/self-efficacy/quality of life, in individuals with schizophrenia? Will the gaming component strengthen motivation for a physically more intensive component, so that attendance will be at least as high as in comparable exercise studies despite the current study being implemented in a resource-limited, regular clinical outpatient setting? Participants will be asked to engage in two 45 minutes exergaming sessions with a designated personal trainer for 12 weeks. Results pre- and post intervention will be compared, and comparisons will also be made with a former randomized controlled trial conducted at the same site, in which the currently combined activities were investigated separately (high-intensity interval training and low-intensity video gaming), both yielding positive but different effects.
Eligibility Criteria
Inclusion Criteria: * Having consent capability * Understanding and speaking Scandinavian language * Fulfilling the International Classification of Diseases Tenth Revision (ICD 10) criteria for schizophrenia spectrum disorder (schizophrenia, schizoaffective disorder and schizophreniform disorder) Exclusion Criteria: * Diagnosis of intellectual disability * Diagnosis of neurological disorder * History of severe head trauma * Pregnancy * Chest pain during exercise * Unstable angina pectoris * Malignant hypertension * Uncontrollable arrhythmia * Recent myocardial infarction * Acute infection with lymphadenopathy * Other specified medical condition incompatible with participation
Contact & Investigator
Tom Langerud Holmen, PhD
PRINCIPAL INVESTIGATOR
Sykehuset i Vestfold HF
Frequently Asked Questions
Who can join the NCT05858255 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Schizophrenia; Psychosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05858255 currently recruiting?
Yes, NCT05858255 is actively recruiting participants. Contact the research team at lantom@siv.no for enrollment information.
Where is the NCT05858255 trial being conducted?
This trial is being conducted at Tønsberg, Norway.
Who is sponsoring the NCT05858255 clinical trial?
NCT05858255 is sponsored by Sykehuset i Vestfold HF. The principal investigator is Tom Langerud Holmen, PhD at Sykehuset i Vestfold HF. The trial plans to enroll 48 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.